CA2303426A1 - Contrast-enhanced diagnostic imaging method for monitoring interventional therapies - Google Patents

Contrast-enhanced diagnostic imaging method for monitoring interventional therapies Download PDF

Info

Publication number
CA2303426A1
CA2303426A1 CA002303426A CA2303426A CA2303426A1 CA 2303426 A1 CA2303426 A1 CA 2303426A1 CA 002303426 A CA002303426 A CA 002303426A CA 2303426 A CA2303426 A CA 2303426A CA 2303426 A1 CA2303426 A1 CA 2303426A1
Authority
CA
Canada
Prior art keywords
contrast
tissue
diagnostic imaging
imaging method
state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002303426A
Other languages
French (fr)
Other versions
CA2303426C (en
Inventor
Randall B. Lauffer
Stephen O. Dunham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantheus Medical Imaging Inc
Original Assignee
Epix Medical, Inc.
Randall B. Lauffer
Stephen O. Dunham
Epix Pharmaceuticals, Inc.
Lantheus Medical Imaging, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical, Inc., Randall B. Lauffer, Stephen O. Dunham, Epix Pharmaceuticals, Inc., Lantheus Medical Imaging, Inc. filed Critical Epix Medical, Inc.
Publication of CA2303426A1 publication Critical patent/CA2303426A1/en
Application granted granted Critical
Publication of CA2303426C publication Critical patent/CA2303426C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Abstract

The present invention relates to a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies.
The contrast agents useful in this method comprise an image-enhancing moiety (IEM) and a state-dependent tissue binding moiety (SDTBM).
These contrast agents exhibit state-dependent binding to one or more components of a targeted tissue or tissue component and provide a detectable change in the signal characteristics of the agent once bound to the targeted tissue. As a result, these agents exhibit a binding affinity for, and thus image contrast of, the targeted tissue which changes as the tissue-state changes during therapy.
CA002303426A 1997-10-02 1998-09-24 Contrast-enhanced diagnostic imaging method for monitoring interventional therapies Expired - Fee Related CA2303426C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94298997A 1997-10-02 1997-10-02
US08/942,989 1997-10-02
PCT/US1998/020182 WO1999017809A2 (en) 1997-10-02 1998-09-24 Contrast-enhanced diagnostic imaging method for monitoring interventional therapies

Publications (2)

Publication Number Publication Date
CA2303426A1 true CA2303426A1 (en) 1999-04-15
CA2303426C CA2303426C (en) 2008-09-23

Family

ID=25478927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303426A Expired - Fee Related CA2303426C (en) 1997-10-02 1998-09-24 Contrast-enhanced diagnostic imaging method for monitoring interventional therapies

Country Status (20)

Country Link
US (2) US6861045B1 (en)
EP (1) EP1019094B1 (en)
JP (2) JP2001518523A (en)
KR (1) KR20010030854A (en)
AT (1) ATE254479T1 (en)
AU (1) AU742438C (en)
BR (1) BR9812716A (en)
CA (1) CA2303426C (en)
DE (1) DE69819925T2 (en)
DK (1) DK1019094T3 (en)
ES (1) ES2206996T3 (en)
HK (1) HK1030744A1 (en)
HU (1) HUP0101245A3 (en)
IL (1) IL134985A0 (en)
IS (1) IS2041B (en)
NO (1) NO321966B1 (en)
NZ (1) NZ503402A (en)
PT (1) PT1019094E (en)
SK (1) SK4842000A3 (en)
WO (1) WO1999017809A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495118B1 (en) 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
AU742438C (en) * 1997-10-02 2003-05-22 Lantheus Medical Imaging, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
AU1791501A (en) 1999-11-22 2001-06-04 Epix Medical, Inc. Imaging sexual response
EP1251876A2 (en) * 2000-01-22 2002-10-30 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US7186797B2 (en) * 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1572724A4 (en) 2002-03-01 2007-03-14 Dyax Corp Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2004078778A2 (en) 2003-03-03 2004-09-16 Dyax Corp. PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
US7585492B2 (en) 2004-05-18 2009-09-08 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams
WO2005110495A1 (en) * 2004-05-18 2005-11-24 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy control in radiation therapy with proton or ion beams
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
US7667460B2 (en) * 2005-11-29 2010-02-23 Koninklijke Philips Electronics N.V. Distinguishing bound and unbound contrast agents using magnetic resonance
WO2007073792A1 (en) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Process for preparing 4,4- diphenylcyclohexanol
EP2053968A4 (en) 2006-08-17 2015-10-21 Epix Pharm Inc Methods for lymph system imaging
DE102006049821A1 (en) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues
US20100092389A1 (en) * 2008-10-10 2010-04-15 The General Hospital Corporation Detection of atherosclerosis using indocyanine green
WO2010048708A1 (en) * 2008-10-27 2010-05-06 The University Of Western Ontario System and method for magnetic resonance imaging
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
CA2754390A1 (en) 2009-03-19 2010-09-23 Wyeth Llc Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof
EP2531102B1 (en) 2010-02-02 2019-06-19 Koninklijke Philips N.V. Functional imaging
TW201514188A (en) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc Process for manufacture of gadofosveset trisodium monohydrate
EP2983581B1 (en) * 2013-04-08 2023-11-15 Sunnybrook Research Institute Method for imaging biomarkers indicative of cardiac thermal ablation lesions
JP2015087167A (en) * 2013-10-29 2015-05-07 キヤノン株式会社 Image processing method and image processing system
WO2015089505A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Coaxial ablation probe and method and system for real-time monitoring of ablation therapy
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
WO2015196208A2 (en) 2014-06-20 2015-12-23 The General Hospital Corporation Collagen targeted imaging probes
EP3270951B1 (en) 2015-03-16 2020-09-09 California Institute of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
EP3322716A2 (en) 2015-07-15 2018-05-23 California Institute of Technology Il-17f-specific capture agents, compositions, and methods of using and making
US10383590B2 (en) 2015-09-28 2019-08-20 General Electric Company Methods and systems for adaptive scan control
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
US11358982B2 (en) 2016-11-01 2022-06-14 Ohio State Innovation Foundation Methods for the iodination of biomolecules
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2020093055A2 (en) 2018-11-02 2020-05-07 Indi Molecular, Inc. Peptide libraries with non-canonical amino acids
US11638764B2 (en) 2018-11-08 2023-05-02 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250285A (en) 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
IT1269839B (en) 1994-05-26 1997-04-15 Bracco Spa CONJUGATES OF BILIARY ACIDS, THEIR DERIVATIVES WITH METALLIC COMPLEXES AND RELATED USES
TW319763B (en) * 1995-02-01 1997-11-11 Epix Medical Inc
CA2539215A1 (en) 1995-02-01 1996-08-08 Epix Pharmaceuticals, Inc. Diagnostic imaging contrast agents with extended blood retention
DE19529512C2 (en) 1995-08-10 2000-11-23 Siemens Ag Phase contrast MR angiography method and arrangement for carrying out the method
DE19543785A1 (en) 1995-11-24 1997-05-28 Philips Patentverwaltung MR method and arrangement for carrying out the method
CA2247620A1 (en) * 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
IT1283650B1 (en) 1996-08-02 1998-04-23 Bracco Spa HIGH RELAXATION PARAMAGNETIC CHELATES IN SERUM
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
AU742438C (en) * 1997-10-02 2003-05-22 Lantheus Medical Imaging, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
IT1304501B1 (en) 1998-12-23 2001-03-19 Bracco Spa USE OF BILIARY ACID DERIVATIVES CONJUGATED WITH METALLIC COMPLEXES LIKE "BLOOD POOL AGENTS" FOR THE DIAGNOSTIC INVESTIGATION THROUGH RESONANCE

Also Published As

Publication number Publication date
BR9812716A (en) 2000-08-22
HK1030744A1 (en) 2001-05-18
US6861045B1 (en) 2005-03-01
IS5399A (en) 2000-03-10
ATE254479T1 (en) 2003-12-15
ES2206996T3 (en) 2004-05-16
HUP0101245A2 (en) 2001-08-28
EP1019094B1 (en) 2003-11-19
DE69819925D1 (en) 2003-12-24
NO321966B1 (en) 2006-07-31
WO1999017809A2 (en) 1999-04-15
HUP0101245A3 (en) 2003-10-28
IL134985A0 (en) 2001-05-20
AU742438C (en) 2003-05-22
CA2303426C (en) 2008-09-23
NZ503402A (en) 2002-03-01
NO20001707L (en) 2000-05-31
SK4842000A3 (en) 2000-11-07
JP2006077020A (en) 2006-03-23
AU9668698A (en) 1999-04-27
EP1019094A2 (en) 2000-07-19
WO1999017809A3 (en) 1999-05-20
NO20001707D0 (en) 2000-04-03
DK1019094T3 (en) 2004-02-16
JP2001518523A (en) 2001-10-16
PT1019094E (en) 2004-03-31
US7175829B2 (en) 2007-02-13
AU742438B2 (en) 2002-01-03
DE69819925T2 (en) 2004-09-02
US20050118103A1 (en) 2005-06-02
IS2041B (en) 2005-09-15
KR20010030854A (en) 2001-04-16

Similar Documents

Publication Publication Date Title
CA2303426A1 (en) Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
CA2190900A1 (en) Medical device visible when using magnetic resonance imaging
WO1997036619A3 (en) Bioactivated diagnostic imaging contrast agents
EP1031354A3 (en) Polymeric MRI Contrast agents
AU4158596A (en) Calixarene conjugates useful as mri and ct diagnostic imaging agents
EP1716871A3 (en) Diagnostic imaging contrast agents with extended blood retention
AU1239300A (en) Diagnostic medical ultrasound method and system for contrast agent imaging
AU7673594A (en) Ultrasound microscope for imaging living tissues
AU630748B2 (en) Paramagnetic oil emulsions as mri contrast agents
ZA976891B (en) Diagnostic imaging contrast agent.
AU2823795A (en) 2,4,6-triiodo-5-substituted-amino-isophthalate esters useful as x-ray contrast agents for medical diagnostic imaging
AU3697899A (en) Diagnostic agent for mr diagnosis
WO2003013616A8 (en) Ionic and non-ionic radiographic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics
NO954183D0 (en) Diagnostic imaging agent
ZA976889B (en) Diagnostic imaging contrast agent.
WO2001040239A3 (en) Transition metal-cyclopentadienyl-tropane conjugates
AU7178298A (en) Magnetic resonance blood pool agents
SI0806968T1 (en) Diagnostic imaging contrast agents with extended blood retention

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170925